News | May 17, 2007

FDA Puts Medicure’s Ischemia Drug on the Fast Track

May 18, 2007 — Medicure, a biopharmaceutical company focused on the research, development and commercialization of novel compounds to treat cardiovascular disorders, is developing MC-1 for the treatment of acute ischemia and ischemic reperfusion injury, and has received a Fast Track Designation from the FDA for the drug.

Currently, MC-1 has completed two positive Phase 2 studies, one in angioplasty patients and most recently a 901-patient coronary artery bypass graft (CABG) study, called MEND-CABG.

In the MEND-CABG study, patients undergoing coronary artery bypass graft surgery who received biopharmaceutical company Medicure’s lead drug MC-1 in Phase II clinical trails showed a 47 percent decrease in postoperative hearts attacks. MC-1 is currently being evaluated in a Phase 3 trial (MEND-CABG II) that is enrolling up to 3,000 patients undergoing CABG surgery at approximately 120 cardiac surgical centers throughout North America and Europe . Medicure is conducting the Phase 3 study in conjunction with the Duke Clinical Institute (DCRI) and Montreal Heart Institute (MHI). If successful, the trial could lead to approval of MC-1 for sale in the U.S.

"Some doctors have been less inclined to recommend bypass surgery for their patients because of the risk associated with the procedure, including postoperative heart attacks,” stated Dr. Robert Harrington of Duke Clinical Research Institute. “Unfortunately there are currently no approved drugs to specifically lessen that risk."

For more information visit

Related Content

Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals | May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals | May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Overlay Init